2024
Survival and Therapeutic Outcomes in T-Cell Prolymphocytic Leukemia (T-PLL): A Collaborative Multi-Center Study Cohort
Braunstein Z, McLaughlin E, Lingamaneni P, Barta S, Cao M, Chang T, Ganesan N, Luu B, Mehta-Shah N, Shree T, Watkins M, Zain J, Allen P, Paulino D, Adams B, Wang J, Feng A, Marchi E, Roberts N, Wilcox R, Gutierrez M, Frosch Z, Sklarz T, Sethi T, Foss F, Beaven A, Haverkos B, Treitman R, Stevens P, Mishra A, Stuver R, Hampel P, Brammer J. Survival and Therapeutic Outcomes in T-Cell Prolymphocytic Leukemia (T-PLL): A Collaborative Multi-Center Study Cohort. Blood 2024, 144: 982-982. DOI: 10.1182/blood-2024-194242.Peer-Reviewed Original ResearchT-cell prolymphocytic leukemiaProgression-free survivalOverall survivalMedian OSFrontline treatmentT-PLL patientsTherapeutic outcomesMedian follow-up timeT-cell prolymphocytic leukemia cellsResponse rateCompared to CD4Multi-center seriesVenetoclax-based regimensSecond-line treatmentKaplan-Meier methodFollow-up timeSubgroup survival analysisCox proportional hazards modelsComprehensive clinical dataMulti-center studyProportional hazards modelFrontline therapyNodal involvementResponding patientsT-PLL
2022
Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research
Murthy HS, Ahn KW, Estrada-Merly N, Alkhateeb HB, Bal S, Kharfan-Dabaja MA, Dholaria B, Foss F, Gowda L, Jagadeesh D, Sauter C, Abid MB, Aljurf M, Awan FT, Bacher U, Badawy SM, Battiwalla M, Bredeson C, Cerny J, Chhabra S, Deol A, Diaz MA, Farhadfar N, Freytes C, Gajewski J, Gandhi MJ, Ganguly S, Grunwald MR, Halter J, Hashmi S, Hildebrandt GC, Inamoto Y, Jimenez-Jimenez AM, Kalaycio M, Kamble R, Krem MM, Lazarus HM, Lazaryan A, Maakaron J, Munshi PN, Munker R, Nazha A, Nishihori T, Oluwole OO, Ortí G, Pan DC, Patel SS, Pawarode A, Rizzieri D, Saba NS, Savani B, Seo S, Ustun C, van der Poel M, Verdonck LF, Wagner JL, Wirk B, Oran B, Nakamura R, Scott B, Saber W. Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research. Transplantation And Cellular Therapy 2022, 28: 187.e1-187.e10. PMID: 35081472, PMCID: PMC8977261, DOI: 10.1016/j.jtct.2022.01.017.Peer-Reviewed Original ResearchConceptsDisease-free survivalTreatment-related mortalityKarnofsky performance statusT-cell depletionVivo T-cell depletionAllogeneic hematopoietic cell transplantationInferior disease-free survivalHematopoietic cell transplantationOverall survivalT-cell prolymphocytic leukemiaT-PLLPerformance statusInternational BloodCell transplantationProlymphocytic leukemiaLong-term disease-free survivalMarrow Transplant Research databasePoor long-term survivalOutcomes of alloHCTPart of conditioningPost-transplantation relapseSuboptimal performance statusMyeloablative conditioning regimenReduced-intensity conditioningInferior overall survival